









Markets
/
Stocks
/
nasdaq-nerv
/

Minerva Neurosciences Inc

NERV

4.800USD

+0.580+13.74%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

33.57MMarket Cap

LossP/E TTM



Minerva Neurosciences Inc

4.800

+0.580+13.74%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Minerva Neurosciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Minerva Neurosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 57 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 4.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Minerva Neurosciences Inc's Score

Industry at a Glance

Industry Ranking

57 / 392

Overall Ranking

176 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Minerva Neurosciences Inc Highlights

StrengthsRisks

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -2.59, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 8.29M shares, increasing 42.44% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 116.50K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.02.

Analyst Rating

Based on 2 analysts

Hold

Current Rating

4.500

Target Price

+6.64%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Minerva Neurosciences Inc is 7.28, ranking 129 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.28

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.92

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Minerva Neurosciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Minerva Neurosciences Inc is 8.93, ranking 4 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.59, which is -644.32% below the recent high of 14.10 and -134.61% above the recent low of -6.08.

Score

Industry at a Glance

Previous score

8.93

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 57/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Minerva Neurosciences Inc is 6.00, ranking 340 out of 392 in the Biotechnology & Medical Research industry. The average price target is 4.50, with a high of 5.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Hold

Current Rating

4.500

Target Price

+6.64%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Minerva Neurosciences Inc

NERV

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Minerva Neurosciences Inc is 8.41, ranking 64 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.28 and the support level at 4.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.52

Change

1.89

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.074

Buy

RSI(14)

58.067

Neutral

STOCH(KDJ)(9,3,3)

66.820

Neutral

ATR(14)

0.458

High Vlolatility

CCI(14)

90.884

Neutral

Williams %R

15.323

Overbought

TRIX(12,20)

0.305

Sell

StochRSI(14)

58.751

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

4.660

Buy

MA10

4.415

Buy

MA20

4.336

Buy

MA50

4.123

Buy

MA100

3.694

Buy

MA200

2.779

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Minerva Neurosciences Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 118.53%, representing a quarter-over-quarter increase of 319.40%. The largest institutional shareholder is The Vanguard, holding a total of 252.03K shares, representing 0.58% of shares outstanding, with 83.84% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Vivo Capital, LLC

3.93M

Farallon Capital Management, L.L.C.

2.37M

Federated Hermes Global Investment Management Corp.

1.35M

Boehringer Ingelheim International GmbH

1.27M

The Vanguard Group, Inc.

Star Investors

252.03K

-0.01%

Luthringer (Remy)

184.82K

Renaissance Technologies LLC

Star Investors

116.50K

+4.95%

Geode Capital Management, L.L.C.

75.63K

BlackRock Institutional Trust Company, N.A.

72.67K

Race (Geoffrey)

51.32K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Minerva Neurosciences Inc is 1.15, ranking 344 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -0.23. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.